Sagimet Showcases Denifanstat's Promise at MASH Summit
Sagimet Biosciences Inc. (Nasdaq: SGMT) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for metabolic disorders. Their work centers around fatty acid synthase (FASN) inhibitors, which target dysfunctional metabolic and fibrotic pathways. Recently, Sagimet announced an exciting opportunity to present their findings on denifanstat, particularly its anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH). This presentation will take place during the 8th Annual MASH Drug Development Summit, a respected event that promotes progress in liver disease research.
Presentation Details at the MASH Summit
The upcoming presentation will greatly enhance our understanding of denifanstat in the treatment of MASH. Here are the key details:
Presentation Title
Illustrating denifanstat’s unique approach in MASH with mechanistic and clinical data that demonstrate its direct anti-fibrotic effects.
Presenter Information
The session will be led by Marie O’Farrell, Ph.D., the Senior Vice President of Research and Development at Sagimet Biosciences.
Session Overview
This session, titled "Showcasing Antifibrotic Progress, Past Learnings & Innovations to Supercharge MASH Drug Development," aims to highlight key advances in the field and ignite discussions about potential future treatments.
Date and Timing
The oral presentation is set for Thursday, September 26, from 4:15 PM to 4:45 PM ET.
About Sagimet and Denifanstat
Sagimet is at the forefront of developing innovative treatments with its lead drug candidate, denifanstat. This medication is a selective FASN inhibitor, designed as an oral, once-daily pill for effectively managing MASH. Recent trials, particularly the FASCINATE-2 trial, have produced promising results, underscoring denifanstat’s potential to reverse the harmful effects of MASH—a serious public health concern globally.
Understanding MASH: A Global Health Challenge
MASH is a serious liver disease impacting millions of people worldwide. It’s associated with excess fat buildup in the liver and can lead to grave health issues if left untreated. Despite affecting over 115 million individuals, treatment options are scarce, with only one drug approved recently in the U.S. and none in Europe. However, the landscape is evolving, as medical societies strive to improve the understanding and terminology surrounding these liver diseases.
In 2023, significant terminology revisions took place; non-alcoholic fatty liver disease (NAFLD) was rebranded as metabolic dysfunction-associated steatotic liver disease (MASLD). Likewise, nonalcoholic steatohepatitis (NASH) is now known as MASH. This change aims to destigmatize the conditions and provide a clearer classification, fostering greater awareness of liver health issues.
Contact and Further Information
For further inquiries regarding Sagimet and its groundbreaking efforts in liver health, you can reach out to:
Joyce Allaire
LifeSci Advisors
Email: Jallaire@lifesciadvisors.com
Frequently Asked Questions
What is denifanstat, and why is it significant?
Denifanstat is a selective fatty acid synthase (FASN) inhibitor developed by Sagimet specifically to address MASH, given the serious implications this disease has for liver health.
Where and when will the MASH presentation take place?
The oral presentation that highlights denifanstat's findings will occur at the MASH Drug Development Summit on September 26, from 4:15 PM to 4:45 PM ET.
What recent changes have been made to liver disease terminology?
This year, NAFLD was renamed to MASLD, while NASH is now called MASH, aiming to offer greater clarity regarding these conditions.
How many people are affected by MASH globally?
MASH significantly impacts over 115 million individuals around the world, emphasizing the urgent need for effective treatment options.
What makes the MASH Summit an essential event?
The MASH Summit provides an important venue for researchers and practitioners to exchange innovations, insights, and advancements, which are crucial for effectively tackling liver diseases.
